Pharmacogenetics of alcoholism: A clinical neuroscience perspective

Pharmacogenomics

Volumn 13, Issue 2, 2012, Pages 129-132

  Ray, Lara A ^a   Courtney, Kelly E ^a   Bujarski, Spencer ^a   Squeglia, Lindsay M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

pharmacotherapy; alcoholism; clinical neuroscience; pharmacogenomics; treatment

Indexed keywords

MU OPIATE RECEPTOR; NALTREXONE;

ALCOHOL INTOXICATION; ALCOHOLISM; BINDING AFFINITY; DOPAMINERGIC SYSTEM; ENDOPHENOTYPE; GABAERGIC SYSTEM; GENE FREQUENCY; HEREDITY; HUMAN; NEUROPHARMACOLOGY; NEUROSCIENCE; PHARMACOGENETICS; PHENOTYPE; REINFORCEMENT; REVIEW; REWARD; RISK FACTOR; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALCOHOLISM; ALLELES; DISULFIRAM; GENETIC MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TAURINE;

EID: 84855956502     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.173     Document Type: Review

References (20)

1. Prescott CA, Kendler KS. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am. J. Psychiatry 156(1), 34-40 (1999). (Pubitemid 29034877)
2. Schuckit MA, Smith TL. An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch. Gen. Psychiatry 53(3), 202-210 (1996). (Pubitemid 26085201)
3. King AC, de Wit H, McNamara PJ, Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch. Gen. Psychiatry 68(4), 389-399 (2011).
4. Ray LA, Mackillop J, Monti PM. Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst. Use Misuse 45(11), 1742-1765 (2010).
5. Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr. Pharm. Des. 16(19), 2141-2148 (2010).
6. Hines LM, Ray L, Hutchison K, Tabakoff B. Alcoholism: the dissection for endophenotypes. Dialogues Clin. Neurosci. 7(2), 153-163 (2005). (Pubitemid 40961535)
7. Eng MY, Luczak SE, Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res. Health 30(1), 22-27 (2007).
8. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem. 9(11), 999-1015 (2009).
9. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64(9), 1069-1077 (2007). (Pubitemid 47360852)
10. Bond C, LaForge KS, Tian M et al. Single-nucleotide polymorphism in the human μ-opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16), 9608-9613 (1998). (Pubitemid 28506279)
11. Ray LA, Hutchison KE. A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin. Exp. Res. 28(12), 1789-1795 (2004). (Pubitemid 39665194)
12. Ramchandani VA, Umhau J, Pavon FJ et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16(8), 809-817 (2011).
13. Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28(8), 1546-1552 (2003). (Pubitemid 41070891)
14. Anton RF, Oroszi G, O'Malley S et al. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65(2), 135-144 (2008). (Pubitemid 351222547)
15. Gelernter J, Gueorguieva R, Kranzler HR et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin. Exp. Res. 31(4), 555-563 (2007). (Pubitemid 46434892)
16. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF. The role of the Asn40Asp polymorphism of the μ-opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin. Exp. Res. doi:10.1111/j.1530-0277.2011.01633.x (2011) (Epub ahead of print).
17. Heilig M, Goldman D, Berrettini W, O'Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat. Rev. Neurosci. 12(11), 670-684 (2011).
18. Johnson BA, Ait-Daoud N, Seneviratne C et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 168(3), 265-275 (2011).
19. Shields AE. Ethical concerns related to developing pharmacogenomic treatment strategies for addiction. Addict. Sci. Clin. Pract. 6(1), 32-43 (2011).
20. Ray LA, Bujarski S, Chin PF, Miotto K. Pharmacogenetics of naltrexone in Asian-Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology doi:10.1038/npp.2011.192 (2011) (Epub ahead of print).